US Broker Ratings

Galapagos NV (GLPG) Stock Analysis: Navigating Uncharted Biotech Waters Amidst a -23% Potential Downside

Galapagos NV (NASDAQ: GLPG), a Belgium-based biotechnology firm, is at a crossroads as it navigates the challenging waters of the healthcare sector. With a current market capitalization of $2.24 billion,..

Haemonetics Corporation (HAE) Stock Analysis: Uncovering a 53.65% Potential Upside Amid Healthcare Innovation

Haemonetics Corporation (NYSE: HAE), a prominent player in the healthcare sector, specializes in medical devices and technologies crucial for modern hospital operations. With a market capitalization of $2.47 billion, Haemonetics..

GeneDx Holdings Corp. (WGS) Stock Analysis: Decoding Growth Potential in the Genomics Sector

GeneDx Holdings Corp. (WGS), a pivotal player in the healthcare sector, stands at the forefront of the diagnostics and research industry. With a market capitalization of $3.73 billion, the company’s..

Ascentage Pharma Group Internat (AAPG): Analyst Ratings Indicate a Promising Future in Biotechnology

Ascentage Pharma Group International (AAPG), a prominent player in the biotechnology sector, is attracting attention with its innovative approach to treating some of the most challenging health conditions, including cancer..

Concentra Group Holdings Parent (CON) Stock Analysis: A Robust 34.76% Upside Potential in the Healthcare Sector

Concentra Group Holdings Parent, Inc. (CON), a formidable player in the healthcare sector, has emerged as a compelling prospect for investors. Specializing in occupational health services, Concentra not only addresses..

Envista Holdings Corporation (NVST) Stock Analysis: A Healthcare Innovator with a Modest Upside

Envista Holdings Corporation (NYSE: NVST), a notable player in the healthcare sector, specializes in the development and distribution of dental products, offering a diverse range of solutions across its Specialty..

Harmony Biosciences Holdings (HRMY) Stock Analysis: Unveiling a 56.19% Potential Upside in the Biotech Sector

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) stands out as a compelling investment opportunity in the biotechnology industry, particularly for investors seeking exposure to the healthcare sector. With a market capitalization..

Organon & Co. (OGN) Stock Analysis: Exploring a 24.57% Potential Upside in the Healthcare Sector

As a key player in the healthcare sector, Organon & Co. (NYSE: OGN) presents a compelling narrative for investors who are keen on exploring opportunities within the drug manufacturing industry...

Ardent Health, Inc. (ARDT) Stock Analysis: A Strong Buy with 46% Potential Upside

Ardent Health, Inc. (ARDT) is making waves in the healthcare sector, particularly within the medical care facilities industry in the United States. With a market capitalization of $1.86 billion, Ardent..

NovoCure Limited (NVCR) Stock Analysis: Unpacking a Potential 107.70% Upside in the Innovative Oncology Device Sector

NovoCure Limited (NASDAQ: NVCR) is a standout player in the healthcare sector, particularly within the medical devices industry. Known for its pioneering work in oncology, NovoCure is at the forefront..

Vericel Corporation (VCEL): Investor Outlook with a 73% Potential Upside

Vericel Corporation (VCEL), a key player in the biotechnology sector, offers a promising investment opportunity for those interested in the healthcare space. With a market capitalization of $1.61 billion, Vericel..

Merus N.V. (MRUS) Stock Analysis: Strong Buy Ratings and a Potential 32% Upside Ignite Investor Interest

Merus N.V. (NASDAQ: MRUS), a Dutch biotechnology pioneer in the healthcare sector, has been capturing investor attention with its robust pipeline of bispecific antibody candidates. Headquartered in Utrecht, Merus is..

Belite Bio, Inc (BLTE) Investor Outlook: Exploring a Promising 30.80% Upside Potential

Belite Bio, Inc (NASDAQ: BLTE), a burgeoning player in the biotechnology sector, is capturing the attention of investors with its innovative approach to tackling unmet medical needs in retinal degenerative..

Amedisys Inc (AMED) Stock Analysis: Navigating Growth in the Healthcare Sector Amid Revenue Expansion

Investors looking for opportunities in the healthcare sector might find Amedisys Inc (AMED) an intriguing prospect, particularly given its strategic positioning in the rapidly evolving home healthcare industry. With a..

QuidelOrtho Corporation (QDEL) Stock Analysis: Unveiling a Potential 52.6% Upside in the Medical Devices Sector

QuidelOrtho Corporation (NASDAQ: QDEL), a prominent player in the healthcare sector focusing on diagnostic testing solutions, presents an intriguing investment opportunity for those monitoring the medical devices industry. Headquartered in..

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: Assessing a 27% Potential Upside Amidst Market Challenges

DENTSPLY SIRONA Inc. (NASDAQ: XRAY), a stalwart in the healthcare sector specializing in medical instruments and supplies, presents an intriguing opportunity for investors seeking exposure in the dental equipment market...

ICU Medical, Inc. (ICUI) Stock Analysis: A Healthcare Innovator with 34.86% Potential Upside

Investors seeking opportunities in the healthcare sector may find ICU Medical, Inc. (NASDAQ: ICUI) an appealing prospect. With a market capitalization of $3.26 billion, this U.S.-based company operates predominantly in..

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Can Investors Capture a 194% Potential Upside?

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a leading biopharmaceutical company, is stirring interest among investors with its impressive potential upside of 194.86%. Specializing in treatments for rare and ultra-rare genetic diseases,..

CRISPR Therapeutics AG (CRSP)

⚠️ No article content returned.

..

MoonLake Immunotherapeutics (MLTX) Stock Analysis: A 39.57% Upside Potential in Biotech Innovation

MoonLake Immunotherapeutics (NASDAQ: MLTX), a Swiss-based biotechnology firm, is making waves in the healthcare sector with its innovative approach to treating inflammatory diseases. Specializing in the development of Sonelokimab, a..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds